Skip to content

Advertisement

  • Guideline
  • Open Access
  • Open Peer Review

How should individual participant data (IPD) from publicly funded clinical trials be shared?

  • 1Email author,
  • 1,
  • 2,
  • 3,
  • 4,
  • 5 and
  • 1
BMC Medicine201513:298

https://doi.org/10.1186/s12916-015-0532-z

©  Tudur Smith et al. 2015

  • Received: 25 August 2015
  • Accepted: 24 November 2015
  • Published:
Open Peer Review reports

Abstract

Background

Individual participant data (IPD) from completed clinical trials should be responsibly shared to support efficient clinical research, generate new knowledge and bring benefit to patients. The Medical Research Council (MRC) Hubs for Trials Methodology Research (HTMR) has developed guidance to facilitate the sharing of IPD from publicly funded clinical trials.

Methods

Development of the guidance was completed over four phases which included a focussed review of policy documents, a web-based survey of the UK Clinical Research Collaboration (CRC) Registered Clinical Trials Units (CTU) Network, participation of an expert committee and an open consultation with the UKCRC Registered CTU Network. The project was funded by the MRC HTMR (MR/L004933/1-R39).

Results

Good practice principles include: (i) the use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access; (ii) seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and (iii) establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD. The guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UKCRC Registered CTU Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.

Conclusions

Implementation of these principles will improve transparency, increase the coherent sharing of IPD from publicly funded trials, and help publicly funded trials to adhere to trial funder and journal requirements for data sharing.

Keywords

  • Data sharing
  • Individual participant data
  • IPD
  • Clinical trial
  • Publicly funded
  • CTU
  • Good practice

Background

Before a clinical trial begins recruiting participants the trial should be ‘registered’ in a clinical trials registry such as ClinicalTrials.gov. This public record of completed and ongoing trials assures transparency and reduces the potential for publication bias, which is known to be a significant problem in medical research [1]. During a clinical trial data are collected about each individual participant. This may include participant characteristics (e.g. age, gender), clinical measurements (e.g. blood pressure, heart rate), medical history (e.g. history of diabetes), clinical laboratory results (e.g. white blood cell count), images (e.g. X-rays), adverse events (e.g. gastrointestinal bleeding events), clinical outcome (e.g. death), and details of randomisation and treatment received. These data are referred to as individual participant data (IPD).

At the end of a clinical trial, results are generated by summarising the IPD to evaluate the effect of interventions administered during the clinical trial. The summary results should be fully reported and published in medical journals [2] and trial registries, but utility of the IPD continues as they provide enormous potential to investigate further clinical and/or methodological questions beyond those that the trial had been originally designed to address. Several clinical trial funders and journals now require that the IPD from a clinical trial is made available on reasonable request [3–6] after completion of the trial.

There are numerous examples in the medical literature that demonstrate the value of IPD and what can be achieved through data sharing. This includes improving the reliability and robustness of comparative meta-analyses in cancer [7], cardiovascular disease [8] and epilepsy [9]; the reliable identification of subgroups of patients that benefit most from treatment [10]; aiding the development of new methodology [11]; and providing the best evidence to inform the development of clinical guidelines [12] and new clinical trials [13]. Greater access to IPD and clinical study reports has been incredibly useful to help overcome the problem of bias in the medical literature with high profile examples focussing on Tamiflu [14] and Paroxetine [15], in which more reliable and balanced information has been generated for patients and clinical practitioners.

Despite the advantages and potential usefulness, IPD is often unavailable [16–18], or may be shared but using responsive ad hoc approaches which limits discoverability, productivity and the potential preservation of valuable data sets. Failure to exploit existing data means that new data are collected unnecessarily which creates unacceptable waste in clinical research [19]. Attitudes are changing, and the pharmaceutical industry [20, 21], drug regulators [22] and the clinical trial community [23, 24] are taking steps to improve things. For the publicly funded trials sector there are examples of good practice [25] but progress towards sharing IPD from clinical trials using a cohesive and consistent approach is slow. More now needs to be done to encourage proactive sharing using common principles of good practice.

In this article we summarise the process used to develop a guidance document for publicly funded clinical trials and outline the key principles of good practice that aim to increase and improve the uptake of responsible data sharing in this key stakeholder group.

Methods

Development of the guidance was funded by the Medical Research Council (MRC) Network of Hubs for Trials Methodology Research (HTMR). A project group including statisticians, clinical trialists, systematic reviewers and methodologists was established to develop the guidance, a process that was completed over four phases.

During phase 1 a focussed search for data sharing policy documents was conducted to identify good practices for responsible sharing of IPD. We searched ‘Google Search’ and the University of Liverpool Discover database (search terms provided in Additional file 1). We used NVivo software to assist the management and indexing of themes and sub-themes identified within and across policy documents. We created theme summary reports to assist the development of guidance.

During phase 2 a web-based survey of the UK Clinical Research Collaboration (CRC) Registered Clinical Trials Units (CTU) Network was undertaken to ascertain current data sharing activities, good practices and possible barriers to sharing IPD from the perspective of organisations coordinating publicly funded clinical trials. Full details of the survey methods and results have been published elsewhere [26]. In brief, a 47-item questionnaire was developed and conducted online using SelectSurvey.NET. Ethical approval was obtained from the University of Liverpool Research Ethics Committee and as the survey was conducted online, completion was regarded as consent to participate. A link to the survey was emailed to the Directors of 45 CTUs within the UKCRC Registered CTU Network in April 2014, with email reminders sent after 2, 4 and 6 weeks. The questionnaire took approximately 15 minutes to complete.

The project group used the information gathered from phase 1 and 2 to develop a draft guidance document summarising the principles of good practice. During phase 3 the draft guidance was circulated to a committee of 13 selected experts, with six representatives from UK publicly funded CTUs that generate clinical trial IPD or UK academic institutions with expertise in using IPD for research purposes, three from pharmaceutical companies in the UK and US, two from UK clinical trial funding bodies, and two from an independent company with knowledge in the area of sharing clinical trial IPD (Additional file 2: Appendix 4). A one-day meeting involving members of the project group and expert committee was held in London during November 2014 to discuss the guidance, and an iterative process used to update and revise the draft guidance to incorporate comments from the expert committee. During phase 4 the revised guidance was circulated to the Directors of the 45 UKCRC Registered CTU Network and a period of open consultation was used to obtain further comments which were incorporated into the final version of the guidance. The full guidance is available as Additional file 2 and from the MRC HTMR website (http://www.methodologyhubs.mrc.ac.uk/files/7114/3682/3831/Datasharingguidance2015.pdf). The key principles, repeated verbatim from the full guidance, are summarised in this article.

Results

Support for the guidance

The guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UKCRC Registered CTU Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.

Summary of guidance

Results of the survey conducted in phase 2 have been published elsewhere [26]. In brief, the CTUs were supportive of the principle of sharing IPD but common concerns were raised about the inappropriate reuse of clinical trial data, the additional resource required for publicly funded CTUs to prepare and share data, the potential loss of ability to publish further research, and the potential risk to trial participant privacy. The use of a controlled access approach (Fig. 1) such as that used by MRC CTU at University College London (UCL) [25], the Yale University Open Data Access Project (YODA) [27] and Clinical Study Data Request (CSDR) [21] with systems in place to review data access requests from researchers, was the preferred approach and this has been assumed throughout.
Fig. 1
Fig. 1

Flow chart of activities in a controlled access model

The ‘data custodian’ is defined within the guidance as a research group, company, organisation or sponsor that collects, manages and stores data from a clinical trial, and would be responsible for data sharing. The data custodian of publicly funded clinical trials would need to consider a number of data sharing activities that could arise throughout the clinical trial process (Fig. 2, Box 1 and Box 2).
Fig. 2
Fig. 2

Data sharing activities through a clinical trial process

Activities can be separated into those that occur at the level of a data custodian’s organisation and which are applicable across multiple trials (Box 1), and also those activities that occur each time an individual trial is conducted (Box 2). The ‘sponsor’ of the trial has ultimate responsibility for authorising the release of data but in many publicly funded clinical trials the ‘sponsor’ may delegate responsibility for activities of data collection and storage to the ‘data custodian’ (e.g. the Chief Investigator’s hosting University or NHS Trust may be the ‘sponsor’ but the ‘data custodian’ would be the CTU coordinating the trial), and so a clear process is required to ensure that sponsor approval for data sharing is provided. Further details of the principles are provided in the full guidance (Additional file 2).

Box 1 - Good practice at the data custodian (e.g. CTU) level

Policy

  • A data sharing policy should be developed by the data custodian organisation outlining the general approach to data sharing, summarising the elements discussed below. The policy should align with any other overarching policies, e.g. host organisation policy, funder policies

Scope

  • IPD and associated documentation should be made available for all prospective publicly funded clinical trials. Requests for data from historical clinical trials should be dealt with on a case-by-case basis

  • IPD should be made available as soon as reasonably possible, e.g. 18 months after trial completion

Data request process

  • Sponsor approval for data sharing should be sought (sponsor might initially agree principles of data sharing but delegate responsibility for implementing data sharing to the data custodian)

  • Only bona fide research groups should be eligible to access data (e.g. evidenced via CVs and the involvement of a qualified statistician)

  • Data access requests should be made via an application form detailing the specific requirements and the proposed research and publication plan

  • Data access requests should be reviewed against specific criteria by data custodians (e.g. trial statistician and Chief Investigator) or by an external Independent Review Panel. Decisions about requests should be made promptly according to a published schedule (no more than 3 months after receipt of request)

  • Details of all data requests and their outcomes, with clear rationale for any refusals, should be made publicly available. Data requesters should be informed of this in advance

Data release process

  • Data should be made available as soon as possible after approval of requests

  • Data should be made available on a secure server or via other secure data transfer method

  • Supporting documentation should be supplied with the dataset

Data use agreement

  • A data use agreement should be utilised which, at a minimum: (i) prohibits attempts to re-identify or contact trial participants; (ii) addresses any requirements regarding planned outputs of proposed research, e.g. publication and acknowledgement requirements; and (iii) prohibits non-approved uses or further distribution of the data

Resources

  • Funds for responsible data sharing should be requested by the original trial team from trial funders as part of initial trial grant applications, e.g. to fund dataset preparation and anonymisation

  • Reasonable costs may be recovered from data requesters if appropriate but data sharing activities should not be profit generating

  • Host organisations (e.g. Institute of Higher Education) may be able to provide funds for routine data sharing activities, e.g. ongoing maintenance of a data sharing system

  • Responsibilities of staff for data sharing should be determined and funding should be sourced

Box 2 - Good practice at the individual trial level

Prior to trial funding

  • Identify data sharing stakeholders for a trial early on (e.g. sponsor, funder, Chief Investigator, trial management group, CTU) and highlight the data sharing policy

  • Understand the trial funder’s policy and include plans and reasonable costs (if appropriate) for sharing IPD within the trial grant application

During trial set-up

  • Identify roles and responsibilities for data sharing activities and include on a delegation log

  • Include outline plans for data sharing in the protocol (see SPIRIT checklist item 31c [28])

  • Include detailed plans for data sharing in the trial data management plan

  • Include a data sharing statement in the consent form and information in the patient information leaflet. The Health Research Authority [29] currently recommend the following wording: “I understand that the information collected about me will be used to support other research in the future, and may be shared anonymously with other researchers.”

  • Annotate the complete set of blank case report forms (CRFs) so that they clearly describe the data variable labels and values contained within the electronic dataset. This may not be required if dataset specifications and blank CRFs are sufficiently detailed to enable matching of data variables from CRFs to the electronic dataset (note: blank CRFs made available on the organisation’s website, or some other forum, would help researchers identify relevant data that have been collected prior to submitting a formal request for data)

End of trial

  • Prepare the anonymised dataset ready for sharing. The level of anonymisation should be determined in conjunction with other considerations, such as original patient consent and method of data transfer

  • Dataset preparation should be done by individuals with an understanding of data management and basic statistics, with quality control provided by a further individual who is independent of the process

  • Prepare ‘data pack’ ready for sharing. This would typically include: (i) electronic datasets in a suitable format that is recognised by a range of statistical software, that could be easily divided to create a subset of data if required for the use case requested; and (ii) supporting documentation (minimum requirement would be protocol with amendments, blank CRFs, dataset specifications including data variable amendments). Timing of data pack preparation may be reactive or proactive.

Conclusions and discussion

We have developed good practice guidance for organisations that conduct publicly funded clinical trials. Although the guidance has been developed with UK publicly funded trials in mind, many of the principles apply to clinical trials coordinated by the private sector and to organisations conducting clinical trials in countries other than the UK. Implementation of these principles will improve transparency and increase the coherent sharing of IPD to support clinical research and benefit patients. More research is needed to help improve the discoverability of these valuable data [30] and we would recommend that the CONSORT checklist [31] for reporting of randomised controlled trials (RCTs) be updated to include a specific item about data sharing and where IPD for the trial can be located. As many medical journals and clinical trial funders now require authors to make their data available, the wider adoption of the principles outlined in this guidance will aid compliance with funder and journal policies on data sharing.

A UKCRC data sharing task and finish group has recently been established to help encourage sharing IPD from clinical trials and support the implementation of the good practice outlined in this guidance. This is a critical component of this project and we will report on our experiences in due course. Researchers who implement this guidance are strongly encouraged to share their experience of how the principles work in practice to inform future updates of the guidance.

Availability of data

The de-identified survey data will be made available for research purposes by contacting the first author (cat1@liv.ac.uk).

Declarations

Acknowledgements

We are particularly grateful to the following for their contributions and suggestions: Jane Armitage, Sue Bell, Jesse Berlin, Jan Bogaerts, Gill Booth, Claire Daffern, Joanne Eatock, Rob Frost, Carrol Gamble, Jamie Garner, Will Greenacre, Helen Hickey, Sally Hollis, Nazir Lone, Maike Rentel, Richard Riley, Haleema Shakur, Lesley Stewart, Liz Tremain, Peter Varnai and Neil Walker.

Development of the guidance was funded by the Medical Research Council (MRC) Hubs for Trials Methodology Research (MR/L004933/1-R39) led from the North West Hub at the University of Liverpool. The funding body had no role in the design, collection, analysis and interpretation of data; writing of the manuscript; nor in the decision to submit the manuscript for publication. CTS and PRW were funded by the North West Hub for Trials Methodology Research (MR/K025635/1). CH was funded by the MRC (MR/L004933/1-R39). KW was funded by a Wellcome Trust Fellowship (WT095874MF). MS was funded by the MRC. GM was funded by the Scottish Funding Council. MC was funded by Queen’s University Belfast.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Block F Waterhouse Building, Liverpool, L69 3GL, UK
(2)
MRC Clinical Trials Unit, University College London, Aviation House, 125 Kingsway, London, WC2B 6NH, UK
(3)
MRC North West Hub for Trials Methodology Research, Department of Psychological Sciences, Block B Waterhouse Building, Brownlow Street, Liverpool, L69 3GL, UK
(4)
All-Ireland Hub for Trials Methodology Research, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Health Sciences Building, 97 Lisburn Road, Belfast, BT9 7BL, UK
(5)
Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, UK

References

  1. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):iii. ix–xi, 1–193.View ArticlePubMedGoogle Scholar
  2. World Health Organization (WHO). WHO statement on public disclosure of clinical trial results. Geneva: WHO; 2015. Available from: http://www.who.int/ictrp/results/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1. Accessed 8th December 2015.
  3. Loder E, Groves T. The BMJ requires data sharing on request for all trials. BMJ. 2015;350:h2373.View ArticlePubMedGoogle Scholar
  4. Public Library of Science (PLOS). Data availability. San Francisco, CA: PLOS; 2015. Available from: http://journals.plos.org/plosmedicine/s/data-availability#loc-acceptable-data-sharing-methods. Accessed 8th December 2015.
  5. Medical Research Council (MRC). MRC policy and guidance on sharing of research data from population and patient studies. Swindon: MRC; 2011. Available from: http://www.mrc.ac.uk/news-events/publications/mrc-policy-and-guidance-on-sharing-of-research-data-from-population-and-patient-studies/. Accessed 8th December 2015.
  6. Research Councils UK (RCUK). Common principles on data policy. Swindon: RCUK; 2015. Available from: http://www.rcuk.ac.uk/research/datapolicy/. Accessed 8th December 2015.
  7. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJ, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31(23):2854–60.View ArticlePubMedGoogle Scholar
  8. Ying A, Arima H, Czernichow S, Woodward M, Huxley R, Turnbull F, et al. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet. 2015;385(9971):867–74.View ArticlePubMedGoogle Scholar
  9. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials. 2007;8(1):34.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.View ArticlePubMedGoogle Scholar
  11. Riley RD, Price MJ, Jackson D, Wardle M, Gueyffier F, Wang J, et al. Multivariate meta-analysis using individual participant data. Res Synth Methods. 2015;6(2):157–74.View ArticlePubMedGoogle Scholar
  12. National Institute for Health and Clinical Excellence (NICE). The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE clinical guideline CG137. London: NICE; 2012.Google Scholar
  13. Tierney JF, Pignon JP, Gueffyier F, Clarke M, Askie L, Vale CL, et al. How individual participant data meta-analyses have influenced trial design, conduct, and analysis. J Clin Epidemiol. 2015;68(11):1325–35.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012;9(4), e1001201.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Le Noury J, Nardo J, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ. 2015;351:h4320.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Savage CJ, Vickers AJ. Empirical study of data sharing by authors publishing in PLoS journals. PLoS One. 2009;4(9), e7078.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Alsheikh-Ali AA, Qureshi W, Al-Mallah MH, Ioannidis JP. Public availability of published research data in high-impact journals. PLoS One. 2011;6(9), e24357.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Jaspers GJ, Degraeuwe PL. A failed attempt to conduct an individual patient data meta-analysis. Syst Rev. 2014;3:97.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257–66.PubMed CentralView ArticlePubMedGoogle Scholar
  20. European Federation of Pharmaceutical Industries and Associations (EFPIA) and Pharmaceutical Research and Manufacturers of America (PhRMA). Principles for responsible clinical trial data sharing. Brussels/Washington, DC: EFPIA/PhRMA; 2013. Available from: http://www.phrma.org/sites/default/files/pdf/PhRMAPrinciplesForResponsibleClinicalTrialDataSharing.pdf. Accessed 8th December 2015.
  21. Clinical Study Data Request. Available from: www.clinicalstudydatarequest.com.
  22. European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use. EMA/240810/2013. London: European Medicines Agency; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf. Accessed 8th December 2015.
  23. Institute of Medicine. Sharing clinical trial data: maximizing benefits, minimizing risk. Washington, DC: Institute of Medicine; 2015. Available from: http://iom.edu/Reports/2015/Sharing-Clinical-Trial-Data.aspx. Accessed 8th December 2015.
  24. Berlin JA, Morris S, Rockhold F, Askie L, Ghersi D, Waldstreicher J. Bumps and bridges on the road to responsible sharing of clinical trial data. Clin Trials. 2014;11:7–12.View ArticlePubMedGoogle Scholar
  25. Sydes MR, Johnson AL, Meredith SK, Rauchenberger M, South A, Parmar MK. Sharing data from clinical trials: the rationale for a controlled access approach. Trials. 2015;16:104.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Hopkins C, Sydes M, Murray G, Woolfall K, Clarke M, Williamson P, et al. UK publicly-funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns. J Clin Epidemiol. 2015. doi: 10.1016/j.jclinepi.2015.07.002. [Epub ahead of print]
  27. Yale University Open Data Access (YODA) Project. Available from: http://yoda.yale.edu/.
  28. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.View ArticlePubMedGoogle Scholar
  29. Health Research Authority. Consent and participant information. London: Health Research Authority; 2015. Available from: http://www.hra.nhs.uk/resources/before-you-apply/consent-and-participation/consent-and-participant-information/. Accessed 8th December 2015.
  30. Scientific Data. Let’s be pragmatic about clinical data. Scientific Data. 2015;2:150034.Google Scholar
  31. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Tudur Smith et al. 2015

Advertisement

BMC Medicine

ISSN: 1741-7015

Contact us